NCT05956847 The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
| NCT ID | NCT05956847 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xijing Hospital |
| Condition | Gastric Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2023-08-10 |
| Primary Completion | 2028-07-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2023-08-10 with a primary completion date of 2028-07-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ECDNA is almost non-existent in normal cells, but exists in nearly half of human cancer cells, indicating that studying such abnormal DNA is of great significance for our understanding of tumor formation and evolution. The changes in ecDNA expression in intestinal type gastric cancer may be closely related to the occurrence and development of gastric cancer. Dynamic monitoring of changes in ecDNA expression in the gastric mucosa may help predict the occurrence of gastric cancer and guide subsequent treatment. By collaborating with multiple endoscopic centers to conduct gastroscopy biopsies on patients with gastric precancerous lesions, we aim to further explore the role of ecDNA in the occurrence and development of gastric cancer through continuous follow-up.
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-80 years old; 2. Patients who plan to undergo gastroscopy at the endoscopic center and patients who undergo surgical treatment for gastric adenocarcinoma; 3. Endoscopy doctors believe that pathological biopsy is necessary to clarify the pathological diagnosis; 4. No serious diseases or other systemic malignancies in terms of physical and mental health; 5. More than one item of non Atrophic gastritis, Atrophic gastritis, intestinal metaplasia, heterogeneous hyperplasia (low grade intraepithelial neoplasia and high grade intraepithelial neoplasia), and gastric adenocarcinoma; 6. Sign an informed consent form; Exclusion Criteria： 1. Pathological results indicate other malignant tumors of the stomach, such as stromal tumors and lymphoma; 2. The patient and their family members do not agree to use the specimen for later research projects; 3. Before gastroscopy or surgery, neoadjuvant therapy or combined with other malignant tumors; 4. Non R0 resected gastric cancer patients; 5. Pregnant or lactating women; 6. Have a history of drug abuse such as alcohol and tobacco.
Contact & Investigator
Guo Xin
PRINCIPAL INVESTIGATOR
Xijing 986 Hospital
Frequently Asked Questions
Who can join the NCT05956847 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Gastric Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05956847 currently recruiting?
Yes, NCT05956847 is actively recruiting participants. Contact the research team at 15389058362@163.com for enrollment information.
Where is the NCT05956847 trial being conducted?
This trial is being conducted at Xi'an, China.
Who is sponsoring the NCT05956847 clinical trial?
NCT05956847 is sponsored by Xijing Hospital. The principal investigator is Guo Xin at Xijing 986 Hospital. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.